Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab + tafasitamab + lenalidomide
- Development stage
- Phase 2
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
This is an investigational combination therapy consisting of epcoritamab, tafasitamab, and lenalidomide. It is being evaluated in the Phase II REPIFIR trial, sponsored by the Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (GELTAMO), for the treatment of patients with first relapse or refractory large B-cell lymphoma (LBCL). Epcoritamab is a bispecific T-cell engager that targets CD3 on T cells and CD20 on B cells. Tafasitamab is a humanized monoclonal antibody targeting CD19. Lenalidomide is an immunomodulatory agent that enhances the activity of T cells and NK cells. The combination aims to provide a synergistic effect by targeting multiple B-cell antigens and enhancing immune-mediated cell death.
- Other names
- REPIFIR regimen
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)CRBN (Cereblon)
Beyond the preview
Go deeper on epcoritamab + tafasitamab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab + tafasitamab + lenalidomide.